RNsider - thanks for that link .... the SA article certainly makes a good case for a biotech sector rebound in 2022, especially those companies with plenty of cash that won't need to raise capital in the near future .... raising capital at very depressed stock prices is bad news for shareholders.
Market Data 
Markets 
AI
